Monopar Therapeutics Inc. Common Stock ($0.001 par value per share) Capital on Demand™ Sales AgreementMonopar Therapeutics • April 20th, 2022 • Pharmaceutical preparations • New York
Monopar Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with JonesTrading Institutional Services LLC (the “Agent”), as follows:
FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • November 12th, 2020 • Monopar Therapeutics • Pharmaceutical preparations • Delaware
This Indemnification Agreement (this “Agreement”), dated as of __________, is by and between Monopar Therapeutics Inc., a Delaware corporation (the “Company”), and _______________________ (“Indemnitee”).
●] Shares MONOPAR THERAPEUTICS INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 1st, 2019 • Monopar Therapeutics • Pharmaceutical preparations • New York
Monopar Therapeutics Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representative (the “Representative”) an aggregate of [●] shares (the “Firm Shares”) of the common stock, par value $0.001 per share, of the Company (“Common Stock”). The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional [●] shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares”.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 12th, 2021 • Monopar Therapeutics • Pharmaceutical preparations • Illinois
This Executive Employment Agreement (the “Agreement”) is entered into as of May 13, 2021, by and between Jose Octavio Pinto Costa Filho, MD (“Executive”) and Monopar Therapeutics Inc. (the “Company”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • September 10th, 2019 • Monopar Therapeutics • Pharmaceutical preparations • Illinois
This Executive Employment Agreement (the "Agreement") is entered into as of November 1, 2017, by and between Andrew P. Mazar ("Executive") and Monopar Therapeutics Inc. (the "Company").
CONTRIBUTION AGREEMENT (351)Contribution Agreement • September 10th, 2019 • Monopar Therapeutics • Pharmaceutical preparations • Delaware
This Contribution Agreement (this “Agreement”) is entered into as of August 25, 2017 (the “Effective Date”), among TacticGem LLC, a Delaware limited liability company (the “Company”), Monopar Therapeutics Inc., a Delaware corporation (“Monopar”), Gem Pharmaceuticals, LLC, an Alabama limited liability company (“Gem”) and Tactic Pharma, LLC, an Illinois limited liability company (“Tactic”, and collectively with Gem, the owners of 100% of the issued and outstanding limited liability company interests of the Company). The Company, Monopar, Tactic, and Gem are sometimes hereinafter referred to collectively as the “Parties”, and each individually as a “Party”.
AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • August 15th, 2019 • Monopar Therapeutics • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”), effective as of September 24, 2014 (the “Effective Date”), is entered into between Tactic Pharma, LLC, a limited liability company (“TACTIC”), having offices at 1062 Princeton Avenue, Highland Park, IL 60035 and XOMA (US) LLC, a Delaware limited liability company (“XOMA”), having offices at 2910 Seventh Street, Berkeley, California 94710. Each of XOMA and TACTIC are sometimes referred to herein separately as a “Party” and together as “Parties.”
CONSULTING AGREEMENTConsulting Agreement • March 28th, 2024 • Monopar Therapeutics • Pharmaceutical preparations • Illinois
This Consulting Agreement (herein referred to as “Agreement”) is made and entered into on December 13, 2022, effective as of January 1, 2023 (the “Effective Date”), by and between Monopar Therapeutics Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and pRx Consulting, LLC (herein referred to as pRx), a Delaware corporation located at # (each herein referred to as “Party” and collectively as “Parties”).
CANCER RESEARCH UK and CANCER RESEARCH TECHNOLOGY LIMITED and MONOPAR THERAPEUTICS LLC CLINICAL TRIAL AND OPTION AGREEMENT (CTOA)Agreement • March 26th, 2018 • Monopar Therapeutics • Pharmaceutical preparations • New York
Schedule 1 Company Patent Rights Schedule 2 Report Synopsis Headings Schedule 3 Licence from CRT to Company Schedule 4 No Fault Compensation Scheme Schedule 5 Assignment and Licence from Company to CRT Schedule 6 Protocol Schedule 7 Company Materials Schedule 8 Back-Up Antibodies Schedule 9 XOMA Licence Schedule 10 Progress Reports Schedule 11 Clinical Protocol Summary Schedule 12 Escrow Agreement Schedule 13 Technical Agreement
VALIDIVE® OPTION AND LICENSE AGREEMENT BY AND BETWEEN MONOPAR THERAPEUTICS INC. AND ONXEO S.A.Option and License Agreement • August 15th, 2019 • Monopar Therapeutics • Pharmaceutical preparations • New York
THIS OPTION AND LICENSE AGREEMENT (together with any Schedules attached hereto, this “Agreement”) is made and entered into as of June 17, 2016 (the “Effective Date”), by and between Monopar Therapeutics Inc., a Delaware corporation located at 598 Rockefeller Rd, Lake Forest, Illinois 60201, United States of America (“Monopar”), and Onxeo S.A., a French société anonyme à Conseil d’administration located at 49, boulevard du Général Martial Valin, 75015 Paris, France (“Onxeo”). Monopar and Onxeo are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractEmployment Agreement • October 1st, 2019 • Monopar Therapeutics • Pharmaceutical preparations
First Amendment to Employment Agreement between Kim R. Tsuchimoto (“Executive”) and Monopar Therapeutics Inc. (“Company”) dated November 1, 2017. The following amendments are made effective March 1, 2018. All other unrevised sections remain in full force.
MONOPAR THERAPEUTICS INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • March 24th, 2022 • Monopar Therapeutics • Pharmaceutical preparations • Delaware
THIS INCENTIVE STOCK OPTION AGREEMENT (this “Agreement”) is made as of [[grantdate]] (the “Grant Date”) between MONOPAR THERAPEUTICS INC. (the “Company”) and [[firstname]] [[lastname]] (referred to herein as “Participant”). Terms used in this Agreement with initial capital letters without definitions are defined in the Monopar Therapeutics Inc. 2016 Stock Incentive Plan (the “Plan”) and have the same meaning in this Agreement.
MONOPAR THERAPEUTICS INC. NONQUALIFIED STOCK OPTION AGREEMENTNonqualified Stock Option Agreement • March 24th, 2022 • Monopar Therapeutics • Pharmaceutical preparations • Delaware
THIS NONQUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) is made as of [[grantdate]] (the “Grant Date”) between MONOPAR THERAPEUTICS INC. (the “Company”) and [[firstname]] [[lastname]] (referred to herein as “Participant”). Terms used in this Agreement with initial capital letters without definitions are defined in the Monopar Therapeutics Inc. 2016 Stock Incentive Plan (the “Plan”) and have the same meaning in this Agreement.
CONSULTING AGREEMENTConsulting Agreement • May 11th, 2023 • Monopar Therapeutics • Pharmaceutical preparations • Illinois
This Consulting Agreement (herein referred to as “Agreement”) is made and entered into on December 16, 2022, effective as of January 1, 2023 (the “Effective Date”), by and between Monopar Therapeutics Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and pRx Consulting, LLC (herein referred to as pRx), a Delaware corporation located at # (each herein referred to as “Party” and collectively as “Parties”).
CONSULTING AGREEMENTConsulting Agreement • November 9th, 2017 • Monopar Therapeutics • Illinois
This Consulting Agreement (herein referred to as "'Agreement'') is made and entered into as of this December 15, 2016 (the "Effective Date"), by and between Monopar Therapeutics, Inc. (herein referred to as "Monopar'·). a Delaware corporation, located at 5 Revere Dr., Suite 200, Northbrook, IL 60062, and pRx Consulting, LLC (herein referred to as pRx), a Delaware corporation located at # (each herein referred to as 'Party' and collectively as "Parties'').
CONSULTING AGREEMENTConsulting Agreement • March 26th, 2018 • Monopar Therapeutics • Pharmaceutical preparations • Illinois
This Consulting Agreement (herein referred to as “Agreement”) is made and entered into on December 8, 2017, effective as of January 1, 2018 (the “Effective Date”), by and between Monopar Therapeutics, Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 5 Revere Dr., Suite 200, Northbrook, IL 60062, and pRx Consulting, LLC (herein referred to as pRx), a Delaware corporation located at # (each herein referred to as “Party” and collectively as “Parties”).
CONSULTING AGREEMENTConsulting Agreement • March 26th, 2018 • Monopar Therapeutics • Pharmaceutical preparations • Illinois
This Consulting Agreement (herein referred to as "Agreement") is made and entered into as of this December 1, 2016 (the "Effective Date"), by and between Monopar Therapeutics Inc. (herein referred to as "Monopar"), a Delaware limited liability corporation. located at corporation, located at 5 Revere Dr., Suite 200, Northbrook, IL 60062, and Andrew P. Mazar (herein referred to as "MAZAR") who resides at # (each herein referred to as "Party" and collectively as "Parties'').
Chandler Robinson Chief Executive Officer Monopar Therapeutics LLC 598 Rockefeller Road Lake Forest, IL USA 60045 Cancer Research UK Angel Building 407 St John Street London EClV 4AD United KingdomMonopar Therapeutics • March 26th, 2018 • Pharmaceutical preparations
CONSULTING AGREEMENTConsulting Agreement • March 25th, 2021 • Monopar Therapeutics • Pharmaceutical preparations • Illinois
This Consulting Agreement (herein referred to as “Agreement”) is made and entered into on January 30, 2020, effective as of January 1, 2020 (the “Effective Date”), by and between Monopar Therapeutics, Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and pRx Consulting, LLC (herein referred to as pRx), a Delaware corporation located at # (each herein referred to as “Party” and collectively as “Parties”).
AMENDMENT NO. 1 TO CONSULTING AGREEMENTConsulting Agreement • March 24th, 2022 • Monopar Therapeutics • Pharmaceutical preparations
This Amendment No. 1 to Consulting Agreement (herein referred to as “Amendment 1”) is made and entered into on November 17, 2021, by and between Monopar Therapeutics, Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and pRx Consulting, LLC (herein referred to as pRx), a Delaware corporation located at # (each herein referred to as “Party” and collectively as “Parties”).
CONSULTING AGREEMENTConsulting Agreement • November 9th, 2017 • Monopar Therapeutics • Illinois
This Consulting Agreement (herein referred to as "Agreement") is made and entered into as of this December 15, 2016 (the "Effective Date"), by and between Monopar Therapeutics Inc. (herein referred to as "Monopar"), a Delaware limited liability corporation, located at corporation, located at 5 Revere Dr., Suite 200, Northbrook, IL 60062, and Kim.R. Tsuchimoto (herein referred to as "TSUCHIMOTO") who resides at # (each herein referred to as "Party" and collectively as "Parties").
CONSULTING AGREEMENTConsulting Agreement • March 24th, 2022 • Monopar Therapeutics • Pharmaceutical preparations • Illinois
This Consulting Agreement (herein referred to as “Agreement”) is made and entered into on December 24, 2020, effective as of January 1, 2021 (the “Effective Date”), by and between Monopar Therapeutics, Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and pRx Consulting, LLC (herein referred to as pRx), a Delaware corporation located at # (each herein referred to as “Party” and collectively as “Parties”).
CONSULTING AGREEMENTConsulting Agreement • March 24th, 2022 • Monopar Therapeutics • Pharmaceutical preparations • Illinois
This Consulting Agreement (herein referred to as “Agreement”) is made and entered into as of January 1, 2022 (the “Effective Date”), by and between Monopar Therapeutics Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd, Suite 350, Wilmette, IL 60091, and Christopher M. Starr, Ph.D., (herein referred to as “Consultant”), whose principal address is # (each herein referred to as “Party” and collectively as “Parties”).
CONSULTING AGREEMENTConsulting Agreement • March 24th, 2022 • Monopar Therapeutics • Pharmaceutical preparations • Illinois
This Consulting Agreement (herein referred to as “Agreement”) is made and entered into on September 29, 2021, effective as of October 1, 2021 (the “Effective Date”), by and between Monopar Therapeutics, Inc. (herein referred to as “Monopar”), a Delaware corporation, located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, and pRx Consulting, LLC (herein referred to as pRx), a Delaware corporation located at # (each herein referred to as “Party” and collectively as “Parties”).
